Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Fleeman N, Bagust A, Boland A, Dickson R, Dundar R, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N
Record ID 32010000295
English
Authors' objectives:

The remit of this appraisal is to review the clinical effectiveness and cost-effectiveness evidence base for LAP in combination with an AI (LAP + AI) and TRA in combination with an AI (TRA + AI) within their licensed indications for the first-line treatment of patients who have HR+/HER2+ mBC.

Authors' recommendations: Study found lapatinib combined with an aromatase inhibitor (AI) and trastuzumab combined with an AI to be clinically more effective than AI monotherapy for the first-line treatment of patients who have hormone receptor-positive/human epidermal growth factor 2-positive metastatic breast cancer. However, neither of these treatments are cost-effective compared with AIs alone.
Details
Project Status: Completed
URL for project: http://www.hta.ac.uk/2228
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Aromatase Inhibitors
  • Triazoles
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: 2011 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.